A groundbreaking ceremony for the QL Biopharmaceutical (Taizhou) production base in Taizhou Medical High-tech Zone in Taizhou, East China's Jiangsu province, was held on March 28.
A groundbreaking ceremony for the QL Biopharmaceutical (Taizhou) production base takes place on March 28. [Photo/WeChat account: weigg6666]
The base is invested in and operated by Beijing QL Biopharmaceutical Co Ltd, with an investment of 125 million yuan ($18.23 million). It is expected to be completed and put into operation by the end of 2023.
Upon its completion, it will be able to produce 40 million semaglutide injections annually, meeting the needs of more than 3 million diabetes patients and people looking for weight loss solutions.
Beijing QL Biopharmaceutical Co Ltd Chairman Zhang Xujia said that the commencement of the Taizhou production base is an important milestone for the company since its establishment, and also a new starting point for its commercialization.
Beijing QL Biopharmaceutical Co Ltd Chairman Zhang Xujia gives a speech. [Photo/WeChat account: weigg6666]
The core research team of Beijing QL Biopharmaceutical Co Ltd includes several former scientists from Novo Nordisk, a leading pharmaceutical company in the world, who have decades of medicine research and development experience in chronic metabolic diseases.